NCT03787680View on ClinicalTrials.gov

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

January 26, 2023

Study Completion Date

August 31, 2028

Conditions
Prostate Cancer
Interventions
DRUG

Olaparib

300 mg by mouth twice a day for days 1-28 of a 28-day cycle.

DRUG

AZD6738

160 mg by mouth daily for days 1-7 of a 28-day cycle.

Trial Locations (3)

22908

University of Virginia Health System, Charlottesville

48109

University of Michigan Hospital, Ann Arbor

48201

Wayne State University/Karmanos Cancer Institute, Detroit

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER